Eli Lilly and Company (LLY)
Drug Manufacturers - General · Healthcare · $1.01T
Intrinsic Value (Consensus)
$475.68
Current Price
$1122.50
Margin of Safety
-57.6%
57.6% Above Intrinsic Value
Value: $476
Price: $1123
High-growth stock: Eli Lilly and Company trades at 50x earnings. Our models use trailing earnings and may undervalue companies with strong future growth potential. The market may be pricing in growth that traditional valuation models don't fully capture.
Valuation Model Estimates
Current Price: $1122.50
DCF (Discounted Cash Flow)
$745.22
Graham Number
$123.44
Earnings Power Value
$222.82
Relative Value (P/E)
$459.00
Dividend Discount Model
$2076.67
Consensus Value
$475.68
Model Assumptions
Discount Rate
10.3%
Growth Rate
20.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
B
65
Profitability
25/25
Strength
16/25
Valuation
2/25
Growth
22/25
Financial Health Signals
Elevated debt — Debt/Equity ratio is 111%
High P/E ratio (50) — priced for significant growth
Strong profitability — ROE of 78% (above 20% is excellent)
Strong earnings growth (20% YoY)
Key Financials
- EPS (TTM)
- $22.95
- EPS (Forward)
- $27.54
- Book Value
- $29.51
- P/E Ratio
- 50.0
- Forward P/E
- 41.7
- PEG Ratio
- —
- ROE
- 77.8%
- Debt/Equity
- 111%
- Revenue Growth
- 44.7%
- Earnings Growth
- 20.0%
- Dividend Yield
- 0.5%
- Beta
- 0.52
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-16
Source: Yahoo Finance